Parkinson’s disease (PD) is a common progressive, neurodegenerative brain disease that is
promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in
the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive
nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high
sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination
chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and
receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements
in radionuclide imaging in Parkinson’s disease.